

■ Regulation on clinical trials - Comment of the European LeukemiaNet

In the last newsletter, we reported on the draft regulation on clinical trials and the alarming suggestions presented in the rapports from different Committees of the European Parliament. At the beginning of April, a comment of the European LeukemiaNet by Nicola Gökbüget was sent to the rapporteurs. The comment is available to be viewed online. ▶ [ELN comment on draft regulation](#)

■ Update of WP participants

On a half-yearly basis the contact data of active WP participants are updated on the website. The current lists as well as short overviews of the respective lead participants are online now. Please find these lists including the participant's organization, nationality and e-mail address in the section "contact" of every workpackage. ▶ [contact NMC for changes](#)

■ Publications from the Network (selected)

Acute lymphoblastic leukemia

- ▶ Garand R et al. Flow cytometry and IG/TCR quantitative PCR for minimal residual disease quantitation in acute lymphoblastic leukemia: a French multicenter prospective study on behalf of the FRALLE, EORTC and GRAALL. *Leukemia*. 2013 Feb;27(2):370-6.
- ▶ Lhermitte L et al. Receptor kinase profiles identify a rationale for multitarget kinase inhibition in immature T-ALL. *Leukemia*. 2013 Feb;27(2):305-14.

Acute myeloid leukemia

- ▶ Alpermann T et al. Evaluation of the proposed reporting system of the European LeukemiaNet and recommendations for prognosis of acute myeloid leukemia. *Leuk Res*. 2013 Feb;37(2):197-200.
- ▶ Bacher U et al. Molecular mutations are prognostically relevant in AML with intermediate risk cytogenetics and aberrant karyotype. *Leukemia*. 2013 Feb;27(2):496-500.
- ▶ Bacher U et al. Patients with therapy-related myelodysplastic syndromes and acute myeloid leukemia share genetic features but can be separated by blast counts and cytogenetic risk profiles into prognostically relevant subgroups. *Leuk Lymphoma*. 2013 Mar;54(3):639-42.
- ▶ Deschler B et al. Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome. *Haematologica*. 2013 Feb;98(2):208-16.
- ▶ Fasan A et al. GATA2 mutations are frequent in intermediate-risk karyotype AML with biallelic CEBPA mutations and are associated with favorable prognosis. *Leukemia*. 2013 Feb;27(2):482-5.
- ▶ Giebel S et al. The impact of center experience on results of reduced intensity: allogeneic hematopoietic SCT for AML. An analysis from the Acute Leukemia Working Party of the EBMT. *Bone Marrow Transplant*. 2013 Feb;48(2):238-42.
- ▶ Jourdan E et al for the French AML Intergroup. Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. *Blood*. 2013 Mar 21;121(12):2213-23.
- ▶ Li Z et al. Identification of a 24-Gene Prognostic Signature That Improves the European LeukemiaNet Risk Classification of Acute Myeloid Leukemia: An International Collaborative Study. *J Clin Oncol*. 2013 Mar 20;31(9):1172-81.

- ▶ Ossenkoppele G et al. MRD in AML: time for redefinition of CR? *Blood*. 2013 Mar 21;121(12):2166-8.
- ▶ Rego EM et al. Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the International Consortium on APL. *Blood*. 2013 Mar 14;121(11):1935-43.
- ▶ Rucker FG et al. Altered miRNA and gene expression in acute myeloid leukemia with complex karyotype identify networks of prognostic relevance. *Leukemia*. 2013 Feb;27(2):353-61.
- ▶ Walter RB et al. Significance of FAB subclassification of "acute myeloid leukemia, NOS" in the 2008 WHO classification: analysis of 5848 newly diagnosed patients. *Blood*. 2013 Mar 28;121(13):2424-31.

Chronic myeloid leukemia

- ▶ Angelini S et al. Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy. *Haematologica*. 2013 Feb;98(2):193-200.
- ▶ Pavlů J et al. Allogeneic stem cell transplantation for chronic myeloid leukemia. *Curr Hematol Malig Rep*. 2013 Mar;8(1):43-51.

Chronic lymphocytic leukemia

- ▶ Ghielmini M et al; Panel Members of the 1st ESMO Consensus Conference on Malignant Lymphoma. ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). *Ann Oncol*. 2013 Mar;24(3):561-76.
- ▶ Marinelli M et al. Identification of molecular and functional patterns of p53 alterations in chronic lymphocytic leukemia patients in different phases of the disease. *Haematologica*. 2013 Mar;98(3):371-5.
- ▶ Rossi D et al. Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. *Blood*. 2013 Feb 21;121(8):1403-12.
- ▶ Schulz A et al. Lenalidomide reduces survival of chronic lymphocytic leukemia cells in primary cocultures by altering the myeloid microenvironment. *Blood*. 2013 Mar 28;121(13):2503-11.

Chronic myeloproliferative diseases

- ▶ Besses C et al. Cytoreductive treatment patterns for essential thrombocythemia in Europe. Analysis of 3643 patients in the EXELS study. *Leuk Res*. 2013 Feb;37(2):162-8.
- ▶ Silver RT et al. Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis. *Expert Rev Hematol*. 2013 Feb;6(1):49-58.

Myelodysplastic syndromes

- ▶ Bacher U et al. Patients with therapy-related myelodysplastic syndromes and acute myeloid leukemia share genetic features but can be separated by blast counts and cytogenetic risk profiles into prognostically relevant subgroups. *Leuk Lymphoma*. 2013 Mar;54(3):639-42.
- ▶ Christopeit M et al. Evaluation of BM cytology after allo-SCT in patients with MDS. *Bone Marrow Transplant*. 2013 Mar;48(3):465-6.
- ▶ Deschler B et al. Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome. *Haematologica*. 2013 Feb;98(2):208-16.
- ▶ Hartmann J et al. Iron overload impairs proliferation of erythroid progenitors cells (BFU-E) from patients with myelodysplastic syndromes. *Leuk Res*. 2013 Mar;37(3):327-32.
- ▶ Kern W et al. Serial assessment of suspected myelodysplastic syndromes: significance of flow cytometric findings validated by cytology, cytogenetics, and molecular genetics. *Haematologica*. 2013 Feb;98(2):201-7.
- ▶ Kröger N et al. Allogeneic stem cell transplantation for older advanced MDS patients: improved survival with young unrelated donor in comparison with HLA-identical siblings. *Leukemia*. 2013 Mar;27(3):604-9.
- ▶ van de Loosdrecht AA et al. Rationale for the clinical application of flow cytometry in patients with

myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group. *Leuk Lymphoma*. 2013 Mar;54(3):472-5.

Diagnosics

- ▶ Kohlmann A et al. Next-generation sequencing - feasibility and practicality in haematology. *Br J Haematol*. 2013 Mar;160(6):736-53.

Miscellaneous

- ▶ Bates DW et al. Discussion of "attitude of physicians towards automatic alerting in computerized physician order entry systems". *Methods Inf Med*. 2013 Mar 18;52(2):109-27.
- ▶ Clark T et al. Sample size determinations in original research protocols for randomised clinical trials submitted to UK research ethics committees: review. *BMJ*. 2013 Mar 21;346:f1135.
- ▶ Kampa-Schittenhelm KM et al. Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms. *Mol Cancer*. 2013 Mar 7;12(1):19.
- ▶ Köpcke F et al. Evaluation of data completeness in the electronic health record for the purpose of patient recruitment into clinical trials: a retrospective analysis of element presence. *BMC Med Inform Decis Mak*. 2013 Mar 21;13:37.

■ New trials in the ELTR

ENESTFreedom A Single-arm, Multicenter, Nilotinib Treatment-free Remission Study in Patients With BCR-ABL1 Positive Chronic Myelogenous Leukemia in Chronic Phase Who Have Achieved Durable Minimal Residual Disease (MRD) Status on First Line Nilotinib Treatment

EPIC A Phase 3 Randomized, Open-Label Study of Ponatinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase



Support the ELN Foundation ▶

European Leukemia Information Center
Dr. Nicola Gökbüget, Dr. Sina Hehn
Johann Wolfgang Goethe University Hospital
Department of Medicine II | Theodor-Stern-Kai 7
60590 Frankfurt am Main | Germany

ELIC@em.uni-frankfurt.de | www.leukemia-net.org | [unsubscribe](#)